SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is a hot topic amidst a sharp divergence of investor sentiment, primarily driven by its ambitious AI infrastructure expansion and substantial debt. While some highlight its impressive cloud backlog and potential for major AI contracts, others are concerned about increased capital expenditures, recent revenue performance, and a bondholder lawsuit related to debt financing, leading to fervent debate about its future trajectory.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed Inc. is trending as its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access across a large healthcare system. This news, coupled with the stock's low float characteristics, has ignited intense community discussion and propelled highly volatile trading activity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating significant conversation following a notable share price decline, leading to a stark division in community sentiment. Bearish investors express frustration over perceived manipulation and competition from larger players in the health and weight-loss markets. Meanwhile, bullish participants are emphasizing the company's underlying growth, strategic vertical integration in personalized healthcare, and see current levels as a compelling long-term buying opportunity.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is a major talking point due to ongoing legal challenges from Elon Musk concerning its partnership with OpenAI, which coincides with broad community frustration over its recent underperformance. Despite some labeling it "garbage," many investors are eyeing the current pullback as a strategic buying opportunity, betting on its strong fundamentals and anticipating clarity around its significant AI investments ahead of upcoming earnings.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending amidst an unprecedented and accelerating shortage of memory chips, particularly High-Bandwidth Memory (HBM), driven by robust AI infrastructure demand. The community is actively discussing whether its strong performance, fueled by strategic acquisitions and production expansions, signals a sustainable "supercycle" or if the stock is overextended in a historically cyclical industry. Investors are also noting its compelling valuation compared to other AI-driven semiconductor peers.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending with strong bullish momentum, driven by its expanding role in AI infrastructure, including a significant data center lease agreement with Riot Platforms. The community is actively celebrating AMD's robust performance and growing market share in AI GPUs and server CPUs, viewing its sustained strength as a key indicator of leadership in the competitive AI compute race. Many see this as a pivotal moment for AMD's long-term growth trajectory in the burgeoning AI sector.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its Q4 earnings report, which, despite solid membership and ad revenue growth, was met with investor concern over a conservative Q1 outlook and the all-cash Warner Bros. Discovery acquisition proposal. The community is sharply divided, with many seeing the stock as oversold and a long-term buying opportunity, while others express fears of ongoing downside due to acquisition-related debt and a shift in company priorities. The market continues to weigh Netflix's content strategy and future growth trajectory amidst a competitive streaming landscape.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is currently a hot topic as investors eagerly await a crucial shareholder vote on increasing authorized shares, with high speculation that significant government AI contract announcements are being held until after its passage. This has sharply divided the community, with many anticipating a major short squeeze and institutional accumulation in the defense AI sector, while skeptics warn of potential dilution and perceived overvaluation.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant rally, driven by recent analyst upgrades and growing optimism surrounding its strategic turnaround, including advancements in its 18A manufacturing process and Panther Lake processors. The community is actively discussing the company's potential for market share gains, its positioning against sector rivals, and the impact of upcoming earnings. Despite some concerns about a "sell the news" event, widespread bullish sentiment points to a belief in Intel's long-term recovery and its increasing importance in the semiconductor landscape.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing an extraordinary rally, driven by increasing demand for memory and storage solutions amidst an 'unprecedented' AI-fueled shortage, pushing sector-wide prices higher. The stock's 'insane run' and resilience against broader market downturns have ignited intense debate, with many celebrating its upward momentum while others warn of a 'bloated pig' and 'meme-level bubble' poised for correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

Equity

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

BlackRock Institutional Trust Company N.A. - iShares ESG Aware MSCI USA Small-Cap ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$49.16
Prev Close	$48.58
Open	$49.03
Dividend Yield	N/A
50-Day Moving Average	$46.35
Beta	N/A
Avg. Volume	134,533.36
PE Ratio	N/A

52-Week High	$49.51
52-Week Low	$32.91
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ESML
iShares ESG Aware MSCI USA Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ESML News

ESMLiShares ESG Aware MSCI USA Small-Cap ETF